132 related articles for article (PubMed ID: 35112690)
21. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
[TBL] [Abstract][Full Text] [Related]
22. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.
Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697
[TBL] [Abstract][Full Text] [Related]
23. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
24. [GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro].
He SB; Sun K; Wang L; Li DC; Zhang YY
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):410-4. PubMed ID: 20819479
[TBL] [Abstract][Full Text] [Related]
25. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
26. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors.
Wang T; Wang D; Yu H; Feng B; Zhou F; Zhang H; Zhou L; Jiao S; Li Y
Nat Commun; 2018 Apr; 9(1):1532. PubMed ID: 29670088
[TBL] [Abstract][Full Text] [Related]
27. Hybrid Ginseng-derived Extracellular Vesicles-Like Particles with Autologous Tumor Cell Membrane for Personalized Vaccination to Inhibit Tumor Recurrence and Metastasis.
Wang H; Mu J; Chen Y; Liu Y; Li X; Li H; Cao P
Adv Sci (Weinh); 2024 May; 11(17):e2308235. PubMed ID: 38353384
[TBL] [Abstract][Full Text] [Related]
28. [Clinical effects of dendritic cells pulsed with autologous hepatoma cell lysates on the postoperative recurrence and metastasis of hepatocellular carcinoma].
Gao J; Chen M; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):432-5. PubMed ID: 15975277
[TBL] [Abstract][Full Text] [Related]
29. Degradation-regulated architecture of injectable smart hydrogels enhances humoral immune response and potentiates antitumor activity in human lung carcinoma.
Duong HTT; Thambi T; Yin Y; Kim SH; Nguyen TL; Phan VHG; Kim J; Jeong JH; Lee DS
Biomaterials; 2020 Feb; 230():119599. PubMed ID: 31718883
[TBL] [Abstract][Full Text] [Related]
30. Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.
Ravindranathan S; Nguyen KG; Kurtz SL; Frazier HN; Smith SG; Koppolu BP; Rajaram N; Zaharoff DA
Breast Cancer Res; 2018 Oct; 20(1):126. PubMed ID: 30348199
[TBL] [Abstract][Full Text] [Related]
31. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.
Wang CY; Hua R; Liu L; Zhan X; Chen S; Quan S; Chu QJ; Zhu YT
Cancer Med; 2017 Mar; 6(3):689-697. PubMed ID: 28205361
[TBL] [Abstract][Full Text] [Related]
33. Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence.
Gong S; Liang X; Zhang M; Li L; He T; Yuan Y; Li X; Liu F; Yang X; Shen M; Wu Q; Gong C
Small; 2022 Dec; 18(50):e2107061. PubMed ID: 36323618
[TBL] [Abstract][Full Text] [Related]
34. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
35. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
36. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
[TBL] [Abstract][Full Text] [Related]
37. pH-responsive nanocomposite hydrogel for simultaneous prevention of postoperative adhesion and tumor recurrence.
Zhou J; Wang H; Chen H; Ling Y; Xi Z; Lv M; Chen J
Acta Biomater; 2023 Mar; 158():228-238. PubMed ID: 36563777
[TBL] [Abstract][Full Text] [Related]
38. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G
Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317
[TBL] [Abstract][Full Text] [Related]
39. Improvement of a dendritic cell-based therapeutic cancer vaccine with components of Toxoplasma gondii.
Motamedi M; Arab S; Moazzeni SM; Khamis Abadi M; Hadjati J
Clin Vaccine Immunol; 2009 Oct; 16(10):1393-8. PubMed ID: 19656994
[TBL] [Abstract][Full Text] [Related]
40. Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response.
Mashima H; Zhang R; Kobayashi T; Hagiya Y; Tsukamoto H; Liu T; Iwama T; Yamamoto M; Lin C; Nakatsuka R; Mishima Y; Watanabe N; Yamada T; Senju S; Kaneko S; Idiris A; Nakatsura T; Ohdan H; Uemura Y
Oncoimmunology; 2020 Sep; 9(1):1814620. PubMed ID: 33457097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
